WuXi Biologics placements net HK$7.9bn
Chinese pharmaceuticals firm WuXi Biologics and one of its controlling shareholders are set to raise a combined HK$7.9bn ($1bn) from the sale of equal chunks of shares in the company.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts